Sandoz Group Ltd

Sandoz Group Ltd

84.46
EUR
-1.42
(-1.65%)
Sandoz Group Ltd
XETR:D8Y
(Deutsche Borse Xetra)

Recent

price

84.46

P/E

ratio

- -

div

yld

- -

ROIC.AI

No data availableFinancial data will appear here once available

Capital Structure

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Quarterly Revenue

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Company News

  • NBIX vs. SDZNY: Which Stock Should Value Investors Buy Now?

  • GRFS vs. SDZNY: Which Stock Should Value Investors Buy Now?

  • mAbxience and Sandoz Sign a Collaboration Agreement to Advance Biosimilar Access Worldwide

  • Sandoz Gets Canada Approval for Generic Version of Ozempic

  • Sandoz Group AG (SDZNY) Analyst/Investor Day Transcript

  • GRFS or SDZNY: Which Is the Better Value Stock Right Now?

  • Switzerland's Sandoz pivots to biosimilars, expects rapid mid-term growth

  • 3 Generic Drug Stocks to Watch Amid Improving Industry Trends

  • Henlius and Sandoz Enter Strategic Collaboration to Unlock Global Value of Biosimilars Platform

  • Sandoz to license three biosimilar drugs from Shanghai Henlius Biotech

  • Sandoz Group AG (SDZNY) Q2 2026 Earnings Call Transcript

  • Sandoz Shares Climb After Biosimilar Sales Drive Growth

  • Sandoz results narrowly beat sales expectations

  • UTHR or SDZNY: Which Is the Better Value Stock Right Now?

  • Sandoz to Pay Around $480 Million to Settle U.S. Antitrust Pricing Litigations

  • Sandoz agrees $450 mln settlement with 43 US states over antitrust claims

  • Generic drug sector seeks policy fixes after Trump tariff threat

  • Generic drugmaker Sandoz to engage with US after Trump tariff threat

  • FDA set to review Sandoz's generic GLP-1s

  • 3 Generic Drug Stocks to Watch as New Growth Drivers Emerge